🟢 Gossamer Bio is trading 8% up on October 13, 2026 after Chardan initiated coverage with a Buy rating

Gossamer Bio is trading at $10.03, up 8.08%, after Chardan initiated coverage with a Buy rating and a $160 price target. - Chardan cites seralutinib’s FDA approval potential despite the Phase 3 PROSERA trial’s narrow statistical miss. - Chardan named Gossamer Bio its top small-cap pick for 2027; the target reflects optimistic approval and sales assumptions. - No current-session trading volume was reported; supplied market context shows biotech ETF XBI down 2.01%.